alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

110TH CONGRESS 

1ST SESSION H. R. 4861 

To extend the temporary suspension of duty on 2-Amino-5-sulfobenzoic acid. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 19, 2007 

Mr. CLAY introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL 

To extend the temporary suspension of duty on 2-Amino5-sulfobenzoic acid. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 2-AMINO-5-SULFOBENZOIC ACID. 

4 (a) IN GENERAL.—Heading 9902.02.38 of the Har5 monized Tariff Schedule of the United States is amended 

6 by striking ‘‘12/31/2009’’ and inserting ‘‘12/31/2011’’. 

7 (b) EFFECTIVE DATE.—The amendment made by 

8 subsection (a) applies with respect to goods entered, or 

9 withdrawn from warehouse for consumption, on or after 

10 the 15th day after the date of the enactment of this Act. 

Æ 


HMOORE on PRODPC68 with HMBILLS
Exhibit
32



CERTIFICATION
PURSUANT TO

18
U.S.C. SECTION 1350

AS
ADOPTED PURSUANT TO

SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002



In
connection with the Annual Report of HL Acquisitions Corp. (the “Company”) on Form 10-K for the year ended June 30,
2018 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities
and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



|1. | The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                  
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                            
|2. | The information
    contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the
    Company.



|Date: September 18, 2018 | /s/
    Jeffrey E. Schwarz                                
|------------------------ | ----------------------------------------------------------
|                         | Jeffrey E. Schwarz                                        
|                         | Chief Executive Officer
 (Principal Executive
    Officer)



| | /s/
    Greg Drechsler                                    
| | ----------------------------------------------------------
| | Greg Drechsler                                            
| | Chief Financial Officer 
(Principal Financial
    Officer)
Document

Exhibit 10.2

FOURTH AMENDMENT to OPTION FOR A LICENSE AGREEMENT
This Fourth Amendment entered into on the date of last signature to this Fourth Amendment by and between MacroGenics, Inc., a Delaware corporation having a principal office located at 9704 Medical Center Drive, Rockville, MD 20850 (“MacroGenics”), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLC”) and Institute de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la République – 92150 Suresnes – France (“IdRS”) and LLS and IdRS hereinafter collectively referred to as “Servier”). MacroGenics and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties”
WHEREAS, Servier and MacroGenics executed an Option for a License Agreement on September 19th, 2012, as amended on 14th June 2017and 5th March 2018 (the “Agreement”);
WHEREAS, the Parties wish to further amend the Agreement as set forth below;
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to the following terms and conditions:
All capitalized terms used in this Fourth Amendment, but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.
Art I:
Art 1.51 is deleted and replaced by:
“Licensed Product “means any therapeutic or prophylactic product that comprises or incorporates a Program DART as an active pharmaceutical ingredient alone or in combination with one or more other active agents, including in fixed dose combination, whether co-formulated or co-packaged. For the avoidance of doubt, any product (other than a Licensed Compound) that is co-administered with a Licensed Product cannot be considered as a Licensed Product itself.
ART II:
This Fourth Amendment and the Agreement constitute the entire agreement of the parties and supersede any and all prior agreements, written or oral, between Servier and MacroGenics relating to the subject matter of this Fourth Amendment and the Agreement and neither may be amended unless agreed to in writing by both parties.
[Signature page as follows]














Exhibit 10.2

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to be executed by their respective duly authorized representative.


						
	MacroGenics, Inc.	Les Laboratories Servier


Name:__________________________




Title:___________________________




Date:___________________________











		
	Name:__________________________	Name:__________________________
		
	Title:___________________________	Title:___________________________
		
	Date:___________________________	Date:___________________________
		
		
		Institute de Recherches Servier


Name:__________________________




Title:___________________________




Date:___________________________



		
		Name:__________________________
		
		Title:___________________________
		
		Date:___________________________
[ARTICLE] 6
[CIK] 0000091157
[NAME] SHORT-TERM HIGH GRADE BOND FUND - CLASS Y
[SERIES]
   [NUMBER] 004
   [NAME] SMITH BARNEY FUNDS, INC.
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   YEAR
[FISCAL-YEAR-END]                          DEC-31-1999
[PERIOD-END]                               DEC-31-1999
[INVESTMENTS-AT-COST]                      104,410,913
[INVESTMENTS-AT-VALUE]                     102,554,173
[RECEIVABLES]                                1,976,360
[ASSETS-OTHER]                                     293
[OTHER-ITEMS-ASSETS]                                 0
[TOTAL-ASSETS]                             104,530,831
[PAYABLE-FOR-SECURITIES]                             0
[SENIOR-LONG-TERM-DEBT]                              0
[OTHER-ITEMS-LIABILITIES]                      271,195
[TOTAL-LIABILITIES]                            271,195
[SENIOR-EQUITY]                                      0
[PAID-IN-CAPITAL-COMMON]                   113,861,792
[SHARES-COMMON-STOCK]                       12,803,869
[SHARES-COMMON-PRIOR]                       10,902,716
[ACCUMULATED-NII-CURRENT]                       11,939
[OVERDISTRIBUTION-NII]                               0
[ACCUMULATED-NET-GAINS]                    (7,757,355)
[OVERDISTRIBUTION-GAINS]                             0
[ACCUM-APPREC-OR-DEPREC]                   (1,856,740)
[NET-ASSETS]                               140,259,636
[DIVIDEND-INCOME]                                    0
[INTEREST-INCOME]                            6,313,045
[OTHER-INCOME]                                       0
[EXPENSES-NET]                                 878,391
[NET-INVESTMENT-INCOME]                      5,434,654
[REALIZED-GAINS-CURRENT]                   (1,801,419)
[APPREC-INCREASE-CURRENT]                  (2,620,344)
[NET-CHANGE-FROM-OPS]                        1,012,891
[EQUALIZATION]                                       0
[DISTRIBUTIONS-OF-INCOME]                    2,563,190
[DISTRIBUTIONS-OF-GAINS]                             0
[DISTRIBUTIONS-OTHER]                                0
[NUMBER-OF-SHARES-SOLD]                      2,176,626
[NUMBER-OF-SHARES-REDEEMED]                    275,123
[SHARES-REINVESTED]                                 14
[NET-CHANGE-IN-ASSETS]                     (9,826,247)
[ACCUMULATED-NII-PRIOR]                          8,437
[ACCUMULATED-GAINS-PRIOR]                  (5,952,992)
[OVERDISTRIB-NII-PRIOR]                              0
[OVERDIST-NET-GAINS-PRIOR]                           0
[GROSS-ADVISORY-FEES]                          495,532
[INTEREST-EXPENSE]                                   0
[GROSS-EXPENSE]                                878,391
[AVERAGE-NET-ASSETS]                        49,347,007
[PER-SHARE-NAV-BEGIN]                             4.13
[PER-SHARE-NII]                                   0.21
[PER-SHARE-GAIN-APPREC]                         (0.16)
[PER-SHARE-DIVIDEND]                              0.21
[PER-SHARE-DISTRIBUTIONS]                         0.00
[RETURNS-OF-CAPITAL]                              0.00
[PER-SHARE-NAV-END]                               3.97
[EXPENSE-RATIO]                                   0.53
</TABLE>
**
**Exhibit 13.2**

**Certification by the Principal Financial Officer**

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer ofPepper Food Service Co., Ltd., a Japanese corporation (the “Company”), does hereby certify that, to such officer’s knowledge: 

 
1.
The accompanying Annual Report of the Company on Form 20-F for the period ended December 31, 2018(the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 

 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition andresults of operations of the Company. 

Date: April 30, 2019

 
/s/ Kensaku Ichinose                     Kensaku Ichinose Chief Financial Officer **
**EXHIBIT 32.2**

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuantto 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002), I, the undersigned Chief Financial ExecutiveOfficer and Controller of GrayMark Productions, Inc. (the “Company”),hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-QSBof the Company for the three months ended March 31, 2006 (the “QuarterlyReport”) fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934 and that information contained in theQuarterly Report fairly presents, in all material respects, the financialcondition and results of operations of the Company.

 

 
| Date:  May 4, 2006 |   | /S/MARK R. KIDD         |
|-------------------------|--------|-------------------------|
|                    |   | Chief Financial Officer |
|                    |   | and Controller          |

 

----
[Federal Register Volume 87, Number 117 (Friday, June 17, 2022)]
[Notices]
[Page 36472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-13254]


=======================================================================
-----------------------------------------------------------------------

CONSUMER PRODUCT SAFETY COMMISSION


Sunshine Act Meetings

TIME AND DATE: Wednesday, June 22, 2022; 2:00 p.m.

PLACE: The meeting will be held remotely.

STATUS: Commission Meeting--Open to the Public.

Matter To Be Considered:  Decisional Matter: Notice of Proposed 
Rulemaking: Safety Standard for Recreational Off-Highway Vehicle and 
Utility Task/Terrain Vehicle Debris Penetration Hazards.
    All attendees should pre-register for the Commission meeting using 
the following link: https://cpsc.webex.com/cpsc/onstage/g.php?MTID=e4deb22642fc939114f31638cbcb5057e.
    After registering you will receive a confirmation email containing 
information about joining the meeting.

TIME AND DATE: Wednesday, June 22, 2022; 2:00 p.m. (immediately 
following the conclusion of the Public Commission Meeting).

PLACE: The meeting will be held remotely.

STATUS: Commission Meeting--Closed to the Public.

Matter To Be Considered:  Briefing Matter: Commission staff will brief 
the Commission on a compliance matter.

CONTACT PERSON FOR MORE INFORMATION: Alberta E. Mills, Office of the 
Secretary, U.S. Consumer Product Safety Commission, 4330 East-West 
Highway, Bethesda, MD 20814, 301-504-7479 (Office) or 240-863-8938 
(Cell).

    Dated: June 15, 2022.
Alberta E. Mills,
Commission Secretary.
[FR Doc. 2022-13254 Filed 6-15-22; 4:15 pm]
BILLING CODE 6355-01-P
NO.  07-10-0493-CV

	IN THE COURT OF APPEALS

	FOR THE SEVENTH DISTRICT OF TEXAS

	AT AMARILLO

	PANEL D

	JANUARY 26, 2011

	______________________________

In re: LUIS AGUILAR,

				Relator

	______________________________

***OPINION ON ORIGINAL PROCEEDING FOR WRIT OF MANDAMUS***

	______________________________

Before QUINN, C.J., and CAMPBELL and PIRTLE, JJ.

Pending before this court is the application of Luis Aguilar for a writ of mandamus.[footnoteRef:1]  He requests that we “issue Mandamus directing the County Court at Law No. 2 to vacate its unauthorized order of remand and proceed appropriately with determination of the merits of the pending action after the remand is vacated.”  We deny the application. [1: Relator, later, filed an application for writ of prohibition stating that either a writ of prohibition or a writ of mandamus is appropriate.  ] 

In Justice Court, Precinct 2, for Potter County, Aguilar sued Dutcher’s Auto Collision Repair, L.L.C.  The case was tried by that court on May 12, 2010.  A final judgment eventually was entered by the justice court, from which an appeal was taken to the County Court at Law No. 2, for Potter County.  However, the justice court granted a new trial.  That a new trial was so granted was brought to the attention of the county court at law.  The latter then held a hearing, decided, via letter, that granting a new trial resulted in the absence of any judgment to appeal, and ordered that the “matter [be] returned to . . . the trial court for a trial on the merits.”  However, it also directed counsel for Dutcher’s to prepare the requisite order memorializing that decision.    

	We deny Aquilar’s petition for the following reason.  He has an adequate remedy at law through appeal.  *In re C.S.,*277 S.W.3d 82, 84 (Tex. App.–Amarillo 2009, orig. proceeding) (stating that the right to appeal is a remedy at law negating one’s purported entitlement to mandamus relief).   And, the issue to appeal involves whether the county court at law had jurisdiction to entertain an appeal from the justice court.  

	From the tenor of his petition for writ of mandamus, Aguilar simply is asking us to adjudicate whether the county court at law has jurisdiction over the appeal.  It is clear that the county court at law believes it does not given the justice court’s decision to grant a new trial.  However, the latter viewpoint, as well as the decision to remand the cause, apparently has yet to be incorporated into a final, written order.  Once such an order dismissing the appeal for want of jurisdiction is signed, then Aguilar has the legal remedy of appealing the dismissal to this court.  

	Accordingly, the petition for a writ of mandamus is denied.    

Per Curiam

2
**Exhibit 32.1**

 

PHARMACOPEIA DRUG DISCOVERY, INC.

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Inconnection with the Quarterly Report of Pharmacopeia Drug Discovery, Inc.(the “Company”) on Form 10-Q for the period ended March 31,2005, as filed with the Securities and Exchange Commission on the date hereof(the “Report”), I, Leslie J. Browne, Ph.D., President and Chief ExecutiveOfficer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

 

(1) The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

 
| /s/ Leslie  J. Browne, Ph.D.      |   |
|----------------------------------------|--------|
| Leslie  J. Browne, Ph.D.               |
| President  and Chief Executive Officer |
|                                   |
| May 16,  2005                     |

 

----
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, July 16, 2020. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, July 16, 2020 The Court of Appeals hereby passes the following order A20D0411. WASEEM DAKER v. GEORGIA DEPARTMENT OF CORRECTIONS. Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 2020CV331553
# Official Journal C 24/2018

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 24 |
| | |
| English edition | Information and Notices | Volume 6124 January 2018 |

ISSN 1977-091X

Official Journal

of the European Union

C 24

English edition

Information and Notices

Volume 6124 January 2018

---

| Notice No | Contents | page |
| --- | --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2018/C 24/01 | Euro exchange rates | 1 |
| 2018/C 24/02 | New national side of euro coins intended for circulation | 2 |
| | Court of Auditors |
| 2018/C 24/03 | Special Report No 3/2018 — ‘Audit of the Macroeconomic Imbalance Procedure (MIP)’ | 3 |

Notice No

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2018/C 24/01

Euro exchange rates

1

2018/C 24/02

New national side of euro coins intended for circulation

2

Court of Auditors

2018/C 24/03

Special Report No 3/2018 — ‘Audit of the Macroeconomic Imbalance Procedure (MIP)’

3

---

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2018/C 24/04 | Prior notification of a concentration (Case M.8800 — Goldman Sachs/Riverstone Investment/Lucid Energy Group II) — Candidate case for simplified procedure (
  1
  ) | 4 |
| 2018/C 24/05 | Prior notification of a concentration (Case M.8751 — Bell/Hügli) — Candidate case for simplified procedure (
  1
  ) | 6 |
| 2018/C 24/06 | Prior notification of a concentration (Case M.8776 — Macquarie/Allianz/Lakeside Network Investments) — Candidate case for simplified procedure (
  1
  ) | 7 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2018/C 24/04

Prior notification of a concentration (Case M.8800 — Goldman Sachs/Riverstone Investment/Lucid Energy Group II) — Candidate case for simplified procedure (
  1
  )

1

4

2018/C 24/05

Prior notification of a concentration (Case M.8751 — Bell/Hügli) — Candidate case for simplified procedure (
  1
  )

1

6

2018/C 24/06

Prior notification of a concentration (Case M.8776 — Macquarie/Allianz/Lakeside Network Investments) — Candidate case for simplified procedure (
  1
  )

1

7

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance. |

---

(1)   Text with EEA relevance.

1

| EN | |
| --- | --- |

EN
Angela Rene LEEMAN, Petitioner v. ARIZONA

No. 18-1267

Supreme Court of the United States.

October 7, 2019

Petition for writ of certiorari to the Court of Appeals of Arizona, Division Two denied.
STATE OF NORTH CAROLINA v. STEVEN MATTHEW McCLINTON.

No. COA03-426

North Carolina Court of Appeals

Filed September 7, 2004.

This case not for publication

Guilford County No. 02CRS84204.

*Attorney General Roy Cooper, by Assistant Attorney General Richard H. Bradford, for the State.*

*Moshera H. Mohamed for defendant-appellant.*

TIMMONS-GOODSON, Judge.

Steven Matthew McClinton ("defendant")was charged with two counts of robbery with a dangerous weapon in connection with the 7 May 2002 robbery of the Kentucky Fried Chicken restaurant located on West Market Street in Greensboro, North Carolina. Defendant pled guilty pursuant to a plea agreement to one count of robbery with a dangerous weapon. In accordance with the plea agreement the other count of robbery with a dangerous weapon was dismissed, and the trial court sentenced defendant to a presumptive term of 72-96 months imprisonment. Defendant appeals.

Defendant's sole argument on appeal is that the trial court erred in sentencing him outside of the presumptive range withoutfinding the necessary aggravating factors. This argument is wholly without merit.

In the instant case, defendant was convicted of robbery with a dangerous weapon, a Class D felony. The trial court determined, without objection, that defendant had one prior conviction, which resulted in his being a prior record level II offender. The trial court sentenced defendant to a minimum of 72 months and a maximum of 96 months imprisonment.

The minimum and maximum sentences for a particular offense is controlled by G.S. § 15A-1340.17(c) and G.S. § 15A-1340.17(e). The minimum presumptive sentence for a Class D felony committed by a level II offender is anywhere from 61 months to 77 months. *See* N.C. Gen. Stat. § 15A-1340.17(c)(2001). Defendant was then properly sentenced to a presumptive minimum term of 72 months, which is well within the 61-77 month range of sentences set out in G.S. § 15A-1340.17(c). The corresponding maximum term for a 72 month minimum sentence is 96 months. *See* N.C. Gen. Stat. § 15A-1340.17(e). Contrary to defendant's argument, the record shows that he was sentenced in the presumptive range of sentences. The trial court was, therefore, not required to make any written findings in aggravation. *See State v. Bright,*135 N.C. App. 381, 520 S.E.2d 138 (1999) (requiring the trial court to make written findings in mitigation and/or aggravation when deviating from the presumptive range of sentences).

Having so concluded, the judgment of the trial court, entered upon defendant's guilty plea, is affirmed. Affirmed.

Judges CALABRIA and ELMORE concur.

Report per Rule 30(e).